UroAlert - GU Oncology Weekly

May 14, 2026

Videos

Peer-to-Peer Clinical Conversations

Intravesical Mitomycin Hydrogel: Patient-Reported Outcomes Data from OPTIMA II, ATLAS, and ENVISION - Charles Peyton

Charles Peyton

Charles (Chas) Peyton reports patient-reported outcomes data from the OPTIMA II, ATLAS, and ENVISION trials of UGN-102, covering once-weekly intravesical mitomycin in a reverse thermal hydrogel formulation for low-grade intermediate-risk non-muscle invasive bladder cancer.

Initial Experience with APC3 "Presentation" - Philipp Backhaus

At the 2026 UCSF-UCLA PSMA Conference, Philipp Backhaus presents first-in-human imaging and compassionate-use treatment data for OncoACP3-DOTA targeting prostatic acid phosphatase.

Beyond the Abstracts

Partitioned Overall Survival: Comprehensive Analysis of Survival States over 4 Years in CheckMate 9ER Comparing First-Line Nivolumab plus Cabozantinib versus Sunitinib in Advanced Renal Cell Carcinoma - Beyond the Abstract

Detection of Genome-Wide Methylation Changes in Bladder Cancer by Long-Read Sequencing of Urinary DNA - Beyond the Abstract

Conference Coverage

APCCC 2026: Real World Radium-223 Outcomes in Metastatic Castration-Resistant Prostate Cancer: Updated Spanish Tertiary Center Cohort to January 2024

PSMA and Beyond 2026: How PCWG4 Impacts Future Trials

EAU 2026: State-of-the-Art Lecture: Treatment De-Intensification in NMIBC

ASCO GU 2026: The Phase II IVORY Trial: Ivonescimab in Metastatic Clear Cell RCC After Immune Checkpoint Inhibitor Therapy

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.

Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression.

Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial.

Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials

Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes.

Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy.

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.

Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.

Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.

Impact of European Association of Urology Combination and Platinum Eligibility on Real-World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma.

Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer.

The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function.

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists - Beyond the Abstract

Penile & Urethral Cancers

Histological and Molecular Evaluation of HPV in Primary Tumors and Lymph Node Metastases of Penile Cancer.

Quality and readability of online penile-cancer information: a Cross-Sectional Web Study.

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

Renal Cancer

Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement.

Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma.

Clinical profile and management outcomes of small renal masses: a collaborative multi-institutional Indian study led by the society of genitourinary oncologists.

Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma.

PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma.

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

Association Between Polymorphisms in Genes Encoding PD-1/PD-L1 Molecules and Clinicopathological Features in Clear Cell Renal Cell Carcinoma.

Urinary microbiota diversity and composition in patients with advanced renal cell cancer.

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma.

Ablation and Surgery Show Comparable Long-term Outcomes for T1a Renal Cell Carcinoma: A Danish Nationwide Registry Study - Beyond the Abstract

Prostate Cancer

Lifestyle Interventions in Patients in Active Surveillance for Prostate Cancer: A Systematic Review.

Synolitic Graph Neural Networks for MRI-Derived Radiomic-Based Prediction of Prostate Cancer Progression on Active Surveillance.

PSMA PET in Active Surveillance: Initial Experiences and Future Directions.

Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review.

DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer.

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.

The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.

Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.

A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer.

Syncromune®, Inc. Presents Innovative SYNC-T Combination Immunotherapy Approach at Major European Interventional Oncology Conference

The Value of Systematic Versus Targeted Sampling in Prostate Cancer Detection and the Identification of Adverse Pathologic Features: A Retrospective Review of Over 1400 Combined Prostate Biopsies.

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial.

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Prostate Cancer Detection on Micro-Ultrasound Raw Data Using a Deep Learning Neural Network.

Single Port Robotic Radical Prostatectomy: A Propensity-matched Comparison of Transvesical Versus Extraperitoneal Approaches from the Single Port Advanced Research Consortium.

68Ga-PSMA-11 PET/CT for Detecting Biochemical Recurrence after Radical Prostatectomy in a Racially Diverse Population with Low PSA Levels.

Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review.

Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.

Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study.

Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy - Beyond the Abstract

Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the Abstract

Upper Tract Tumors

Conservative Management of Upper Tract Urothelial Carcinoma: A Narrative Review.

Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights.

Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee.

Risk Assessment of Non-Urinary Tract Recurrence After Radical Nephroureterectomy Based on CheckMate 274 Trial Eligibility: A Multicenter Retrospective Study.

Overweight status predicts improved overall survival after radical nephroureterectomy for upper tract urothelial carcinoma.

Testicular Cancer

Lipidomic Plasticity in Testicular Cancer Reflects Diagnostic Signatures in Tissue and Plasma: A Pilot Study.

Microsurgical Onco-Testicular Sperm Extraction in a Patient With Testicular Cancer and Congenital Unilateral Testicular Absence: A Case Report.

Testicular cancer incidence and associations with prior epididymo-orchitis or urinary tract infections: a national cohort study in Sweden, 1964-2018.

Survivorship Outcomes and Patient Perceptions of Care in the Evolved Landscape of Stage I Testis Cancer Management.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC